BPC-157

BPC-157 is a pentadecapeptide, a chain of 15 amino acids with the sequence GEPPPGKPADDAGLV ^[2]. It was described in 1993 by a research group at the University of Zagreb led by Predrag Sikirić, which reported isolating a larger protein, which it called BPC, from gastric juice and characterising a 15-amino-acid fragment thought to carry its activity ^[1]. The name stands for “Body Protection Compound”. The peptide used in research and sold online is made synthetically rather than extracted.

For most of its history BPC-157 was studied by a small number of groups, and the Zagreb group produced the large majority of papers. A 2019 review from Loughborough University noted that “only a handful of research groups” had studied it in depth and that most work was in small rodent models ^[5]. In the early 2000s it was described as being in clinical trials for inflammatory bowel disease under the codes PL 14736 and PLD-116 ^[2], but no results of those trials appear in the peer-reviewed literature we could find.

BPC-157 is one of the most widely discussed peptides sold as a “research chemical”, often alongside TB-500. For background on what that label means and why it matters, see what research peptides are.

No single receptor for BPC-157 has been identified, and proposed mechanisms come from cell and animal experiments. The most consistent theme is blood-vessel formation (angiogenesis). In a 2017 study, BPC-157 increased vessel density in a chick embryo assay and in cultured human endothelial cells, sped recovery of blood flow in rats with an ischaemic hind limb, and increased expression and activation of VEGFR2, a receptor for the growth factor VEGF, along with the downstream Akt–eNOS signalling pathway ^[4].

Tendon cell work points to effects on cell movement rather than cell division. In rat tendon fibroblasts, BPC-157 did not directly increase proliferation but did increase cell survival under oxidative stress and increased migration in a dose-dependent way, which the authors linked to activation of the FAK–paxillin pathway ^[3]. Reviews also describe interactions with the nitric oxide system and reduced inflammatory signalling, but these are drawn from animal models and have not been confirmed in people ^{[6] [7]}.

The best-known experiment is a 2003 rat study in which the Achilles tendon was cut and animals received daily intraperitoneal BPC-157 or saline for up to 14 days. Treated rats showed higher load to failure, better functional scores and more organised collagen and fibroblast formation than controls ^[2]. Similar positive results from the same group followed for muscle and tendon-to-bone injuries, which are summarised in reviews ^{[5] [6]}.

A 2025 systematic review in HSS Journal screened 544 records and included 36 studies, of which 35 were preclinical and one was a clinical study. It concluded that BPC-157 improved functional, structural and biomechanical outcomes in animal models of muscle, tendon, ligament and bone injury, but graded the evidence as level IV and V and found no clinical safety data ^[6]. A 2025 narrative review from the University of Utah reached the same overall view: broad preclinical support, extremely limited human data, and a recommendation that BPC-157 be treated as investigational ^[7].

An independent 2026 study from Turkey compared BPC-157 (10 µg/kg/day), TB-500 (60 µg/kg/day) and the two combined after surgical Achilles repair in 32 rats. BPC-157 produced numerically better tissue scores that did not reach statistical significance for the total scores, while TB-500 showed a significant biomechanical advantage at four weeks; the combination was no better than either alone ^[12]. This is one of the few studies from outside the original research group, and its results for BPC-157 were weaker than earlier reports.

BPC-157 was first investigated as a gut-protective agent. The 1993 overview from its discoverers reported protective effects across many organ systems in several species at very low doses, mostly in the microgram and nanogram per kilogram range ^[1]. Later work from the same group covered stomach and intestinal lesions, fistulas and anastomoses in rats. These are animal findings, often from a single laboratory, and should not be read as evidence of effect in people.

Pharmacokinetic work in rats and beagle dogs, published in 2022, found that BPC-157 has an elimination half-life of under 30 minutes after intravenous or intramuscular injection, that absolute bioavailability after intramuscular injection was about 14–19% in rats and 45–51% in dogs, and that it is broken down into small peptide fragments and amino acids that are excreted in urine and bile ^[11].

There are no published randomised controlled trials of BPC-157. Three small reports, all led by the same first author at private US clinics and published in Alternative Therapies in Health and Medicine, make up the human literature ^[7].

The first was a retrospective chart review of 16 people who had received knee injections. Of 12 who received BPC-157 alone, the authors reported that 11 described significant improvement in pain; four others received BPC-157 with thymosin beta-4. Pain was assessed by telephone survey, with no validated scoring tools and no control group ^[8]. A later systematic review summarised the same study as 7 of 12 patients reporting relief lasting more than six months, which shows how loosely the outcomes were defined ^[6].

The second was a pilot study in 12 women with interstitial cystitis who had not responded to pentosan polysulfate. Each received injections totalling 10 mg of BPC-157 into the bladder wall during a single cystoscopy. The authors reported complete symptom resolution in 10 of 12 and no adverse events, but there was no placebo group ^[9]. The third was a safety pilot in just two adults, who received 10 mg and then 20 mg of BPC-157 by intravenous infusion on consecutive days, with no changes in the blood markers tested and no reported side effects ^[10].

These reports are too small and too uncontrolled to establish whether BPC-157 works or is safe in people.

In the 2003 rat Achilles study, BPC-157 was given by intraperitoneal injection once daily at 10 µg/kg, 10 ng/kg or 10 pg/kg of body weight ^[2]. The 2026 rat study used 10 µg/kg/day intraperitoneally for four weeks ^[12]. These are animal doses and should not be converted to human doses.

In the human pilot reports, the interstitial cystitis study used a total of 10 mg injected into the bladder wall in one procedure ^[9], and the intravenous safety study infused 10 mg on day one and 20 mg on day two in two participants ^[10]. The knee pain chart review did not report a standard dose in its abstract ^[8]. No human dose has been established by any controlled trial, and none of these figures is a recommendation. Our peptide calculator converts vial contents to concentrations, but it does not tell you what amount is appropriate.

Animal studies from the originating group reported no toxicity ^[1], and reviews note few reports of adverse reactions in preclinical work ^[5]. The three human pilot reports described no adverse events, but they involved 30 people in total and short follow-up ^{[8] [9] [10]}. The 2025 systematic review found no clinical safety data and warned that harm is possible from unregulated manufacturing, contamination and unknown effects in humans ^[6].

Because BPC-157 promotes blood-vessel growth in laboratory models ^[4], some reviewers have raised the theoretical question of whether it could affect existing tumours; this has not been studied in people. The US Food and Drug Administration has said that compounded BPC-157 may carry a risk of immune reactions (immunogenicity) for some routes of administration and of peptide-related impurities, and that it lacked the safety information needed to judge whether it would cause harm ^[13].

BPC-157 is not approved as a medicine by the FDA, the UK’s MHRA or any other regulator we are aware of. In the US, the FDA previously placed it in “category 2” of its interim compounding policy, the list of bulk substances that may present significant safety risks; the nomination was later withdrawn and the FDA now lists it among substances previously in category 2 ^[13].

On 23 July 2026, the FDA’s Pharmacy Compounding Advisory Committee considered BPC-157. According to press reports, it voted to recommend that it be added to the list of substances that US pharmacies may use for compounding under section 503A. The FDA's own meeting page had not posted the votes when we checked, committee votes are advisory and not binding, and as of September 2026 we have not confirmed a final FDA decision ^[15]. This would not make BPC-157 an approved drug.

BPC-157 is named on the World Anti-Doping Agency Prohibited List under S0, non-approved substances, and is prohibited at all times for athletes in WADA-compliant sport ^[14]. For country-by-country rules on buying and possessing research peptides, see our legal status overview and the UK page.

Research suppliers sell BPC-157 as a freeze-dried (lyophilised) powder. Like other peptides, the dry powder is generally kept cold and away from light and moisture, and once dissolved it is kept refrigerated and used within a limited period. Our guide on how to store peptides covers the general principles.

Products sold as BPC-157 are unregulated, so purity and identity depend on the supplier. You can compare prices across suppliers we track, learn how to read a COA, and see which vendors use third-party tested batches.